Clinical Trials Browser

Phase 2 × Gliosarcoma × Nivolumab × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT03014804 2020-07-24

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

Glioblastoma, Oligodendroglioma, Gliosarcoma